{"nctId":"NCT00321737","briefTitle":"Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis","startDateStruct":{"date":"2006-05"},"conditions":["Esophagitis, Reflux","Esophagitis, Peptic"],"count":445,"armGroups":[{"label":"Dexlansoprazole MR 30 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Dexlansoprazole MR"]},{"label":"Dexlansoprazole MR 60 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Dexlansoprazole MR"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Dexlansoprazole MR","otherNames":["TAK-390MR","Kapidex","Dexilant"]},{"name":"Dexlansoprazole MR","otherNames":["TAK-390MR","Kapidex","Dexilant"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects must have successfully completed the Phase 3 Study T-EE04-084 (NCT00251693) or T-EE04-085 (NCT00251719); and have healed esophageal erosions proven by endoscopy. Complete healing was assessed for change in LA Esophagitis Classification grades A, B, C, or D to healed (defined as anything less than the criterion for Grade A). The subject was counted as healed if endoscopy findings did not meet the Grade A criterion.\n\nExclusion Criteria:\n\n* Use of prescription or nonprescription proton pump inhibitors (PPIs), histamine (H2) receptor antagonists, sucralfate, misoprostol, or prokinetics throughout the study.\n* Use of antacids (except for study supplied) throughout the study.\n* Use of drugs with significant anticholinergic effects such as tricyclics who cannot stay on a stable dose throughout the study.\n* Chronic (\\>12 doses per month) use of nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors.\n* Need for continuous anticoagulant therapy.\n* Evidence of uncontrolled systemic disease.\n* Subjects who have participated in either maintenance study (T-EE04-086 \\[NCT00255164\\] or T-EE04-087 \\[NCT00255151\\]).\n* Subjects who, in the opinion of the investigator, is unable to comply with the requirements of the study or is unsuitable for any reason.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Crude Rate Analysis.","description":"Crude rates analyzed maintenance of healed EE from baseline of this study and considered prematurely discontinued subjects as relapsed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":null},{"groupId":"OG001","value":"66.4","spread":null},{"groupId":"OG002","value":"66.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Median.","description":"The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":"32.0"},{"groupId":"OG001","value":"96.1","spread":"26.5"},{"groupId":"OG002","value":"90.9","spread":"28.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Mean.","description":"The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.0","spread":"32.0"},{"groupId":"OG001","value":"83.3","spread":"26.5"},{"groupId":"OG002","value":"78.4","spread":"28.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Life Table Method","description":"Percentage of subjects who maintained complete healing of erosive esophagitis as assessed by endoscopy. In the life table method, subjects without post-baseline endoscopy were included as censored; subjects who did not have a recurrence of EE and did not complete the study were also considered censored.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.2","spread":null},{"groupId":"OG001","value":"74.9","spread":null},{"groupId":"OG002","value":"82.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Median.","description":"The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.7","spread":"36.6"},{"groupId":"OG001","value":"98.9","spread":"22.3"},{"groupId":"OG002","value":"96.2","spread":"23.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Mean.","description":"The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.7","spread":"36.6"},{"groupId":"OG001","value":"89.3","spread":"22.3"},{"groupId":"OG002","value":"86.0","spread":"23.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1},"commonTop":["Upper Respiratory Tract Infections","Gastritis (Excl Infective)","Diarrhoea (Excluding [Excl] Infective)","Musculoskeletal and Connective Tissue Signs and Symptoms NEC","Joint Related Signs and Symptoms"]}}}